HOTWIRE
27.4.2021 09:17:05 CEST | Business Wire | Press release
Hotwire , recognised as the pre-eminent global tech communications consultancy, has acquired McDonald Butler Associates (MBA), a strategic B2B sales and marketing agency specializing in the $5.2 trillion technology industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005480/en/
Together, Hotwire’s award-winning communications expertise and MBA’s specific sales and marketing expertise will support CMOs with both near-term sales results and long-term brand building. Synergies between the two firms include a strong tech customer base and a heavy investment in insights, strategy, and creative teams to drive integrated communications programmes. The companies also share a number of clients including Adobe, Citrix, and Dell Technologies.
“Tech CMOs are under pressure to deliver immediate results today and continue building the brand for the future,” said Barbara Bates, Hotwire Global CEO. “By adding MBA’s extensive account-based marketing and channel marketing experience, Hotwire will deliver a new level of communications programmes designed to build brand reputation, strengthen stakeholder relationships and deliver revenue growth.”
This investment gives Hotwire clients access to new skills and services including account-based marketing, industry marketing and channel and alliances programmes. For MBA’s clients, they’ll now have access to a global network, offering an even wider set of communications disciplines including brand development, media relations, corporate communications and deeper expertise in content and social media marketing. Tune into the latest episode of The Hotwire podcast, HotTakes to hear more about the opportunities ahead.
Incorporated in the U.K. in 2005, McDonald Butler supports a strong client roster of technology clients including Accenture, Adobe, AWS, Citrix, Dell Technologies, Deloitte, DXC Technology, Honeywell, IBM, Pegasystems, and PWC.
"This is an extremely exciting opportunity for both MBA’s clients and our team,” said Maeve McDonald, MBA CEO. “Both MBA and Hotwire have been dedicated to helping technology companies solve their most pressing business and communications challenges. Now we have a great opportunity to offer a wider range of communications, lead generation, and digital marketing services to our clients globally.”
Maeve McDonald and Mike Butler, founders of MBA, will take on UK roles of Managing Consultant Account Based Marketing and Marketing respectively, reporting to Tara O’Donnell, UK MD and Global Leadership Team member. Together, the combined team brings Hotwire’s UK headcount to more than 100 and more than 300 globally.
This announcement builds off Hotwire’s continued industry leadership, most recently being named the 2020 Global Technology Agency of the Year by PRovoke Media and its legacy of over 20 years of fuelling positive action for tech companies of all sizes. The investment for the acquisition came from Hotwire’s parent company, Enero Group Limited (ASX: EGG), a boutique network of marketing and communications businesses.
“The acquisition of MBA reflects not only the Group’s strong momentum and ambition but our commitment to deliver on our global strategy of building scale and additional digital capabilities of our core agency brands," said Brent Scrimshaw, Enero Group CEO. “Hotwire is already one of the world’s most highly-regarded tech specialist communication businesses and we have no doubt that adding MBA’s specific sales and marketing expertise and complimentary client roster, will unlock new possibilities of growth.”
About Hotwire
Hotwire is the global technology communications consultancy. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation.
About Enero
Enero Group is a boutique network of marketing and communications businesses listed on the Australian Stock Exchange (ASX:EGG) that includes creative agency BMF, PR agencies Hotwire and CPR, research consultancies The Leading Edge and The Digital Edge, digital agency Orchard and programmatic marketing specialist OBMedia.
For more information, please visit www.enero.com .
About McDonald Butler
McDonald Butler Associates is a strategic B2B sales and marketing agency specializing in Account-Based Marketing, Channel & Alliances, and Industry / Demand Programs for the technology sector. We unite strategic insight and creative cut-through to drive better audience engagement, forge stronger relationships and accelerate sales. We’re proud to be working with some of the world’s largest and most innovative B2B companies, delivering ROI-focused campaigns.
McDonald Butler is passionate about business as a force for good. We are active supporters and advocates of Mellon Educate and Pennies , donating a percentage of our profits and time each year as part of our giving back commitment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005480/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom